Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data

被引：0
|
作者：
Kim A. Papp
Melinda Gooderham
Ignacio Dei-Cas
Adriana LopezTello
Juan C. Garcia-Rodriguez
Carmen Yris Taveras
Azucena Hernández Rousselin
Alberto Lavieri
Mónica Maiolino
Delfina Guadalupe Villanueva Quintero
Lenka Rihakova
Mariano Salibe
Wilfran Pertuz
机构：
[1] K Papp Clinical Research and Probity Medical Research,SKiN Centre for Dermatology and Probity Medical Research
[2] Peterborough and Queen’s University,HIGA Presidente Perón, Servicio de Dermatología, Facultad Medicina UBA
[3] Psoriasis BsAs,undefined
[4] NEKI Servicios Medicos,undefined
[5] Vicente Guerreo,undefined
[6] DermaAdvance Center,undefined
[7] Hospital Regional Universitario Jose Maria Cabral Y Baez,undefined
[8] Hospital Roosevelt,undefined
[9] Calzada Roosevelt,undefined
[10] Private Clinic,undefined
[11] Consultorios Médicos Dr Bouzo,undefined
[12] Grupo Clínico CATEI (Centro de Atención en Enfermedades Inflamatorias) Sociedad Civil,undefined
[13] Novartis Pharmaceuticals Canada Inc.,undefined
[14] Novartis Argentina S.A.,undefined
[15] Novartis Pharma Logistics,undefined
[16] Inc.,undefined
[17] Panama,undefined
来源：
Dermatology and Therapy | 2023年 / 13卷
关键词：
Latin America; Plaque psoriasis; PURE registry; Real-world; Secukinumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：269 / 283
页数：14
相关论文
共 50 条
  • [31] Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study
    Thaci, D.
    Koerber, A.
    von Kiedrowski, R.
    Bachhuber, T.
    Melzer, N.
    Kasparek, T.
    Duetting, E.
    Kraehn-Senftleben, G.
    Amon, U.
    Augustin, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (02) : 310 - 318
  • [32] Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
    April W. Armstrong
    Timothy Fitzgerald
    Robert R. McLean
    Amanda Teeple
    Jonathan P. Uy
    Mobolaji Olurinde
    Katelyn Rowland
    Lin Guo
    Ying Shan
    Kristina Callis Duffin
    Dermatology and Therapy, 2023, 13 : 629 - 640
  • [33] Secukinumab in subjects with moderate-to-severe plaque psoriasis: Results from the Efficacy of Response and Safety of 2 fixed secUkinumab REgimens in psoriasis (ERASURE)
    Elewski, B.
    Lebwohl, M.
    Papp, K.
    Nakagawa, H.
    Sigurgeirsson, B.
    Tsai, T. -F.
    Tyring, S.
    Hampele, I.
    Karpov, A.
    Helou, S.
    Papavassilis, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2014, 55 : 43 - 43
  • [34] Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study
    Zhao, Yan
    Cai, Lin
    Liu, Xiao-Yang
    Zhang, Heng
    Zhang, Jian-Zhong
    CHINESE MEDICAL JOURNAL, 2021, 134 (11) : 1324 - 1328
  • [35] Analysis of efficacy and safety of secukinumab in patients with moderate to severe psoriasis in clinical practice
    Banos Arevalo, Antonio jose
    Barranquero Fernandez, Alvaro
    Herrera Acosta, Enrique
    Suarez Perez, Jorge Alonso
    Gonzalez Saavedra, Jose Andres
    Herrera Ceballos, Enrique
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB43 - AB43
  • [36] Secukinumab in subjects with moderate-to-severe plaque psoriasis: Results from the Efficacy of Response And Safety of 2 fixed secUkinumab REgimens in psoriasis (ERASURE)
    Elewski, B.
    Lebwohl, M.
    Papp, K.
    Nakagawa, H.
    Sigurgeirsson, B.
    Tsai, T.
    Tyring, S.
    Hampele, I.
    Karpov, A.
    Helou, S.
    Papavassilis, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2014, 12 : 15 - 15
  • [37] Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study
    Wu, Nan-Lin
    Hsu, Chih-Jung
    Sun, Fang-Ju
    Tsai, Tsen-Fang
    JOURNAL OF DERMATOLOGY, 2017, 44 (10): : 1129 - 1137
  • [38] Effectiveness and safety of off-label secukinumab dosing regimens for the treatment of moderate-to-severe plaque psoriasis in adult patients: a retrospective multicentre study
    Phung, M.
    Georgakopoulos, J. R.
    Ighani, A.
    Yeung, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E286 - E287
  • [39] Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate- to-severe plaque psoriasis in Spain
    Johansson, Erin
    Nunez, Mercedes
    Svedbom, Axel
    Dilla, Tatiana
    Hartz, Susanne
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 747 - 759
  • [40] DIAGNOSIS OF PSORIATIC ARTHRITIS IN PATIENTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS TREATED WITH SECUKINUMAB VS. OTHER TREATMENTS IN THE PURE REGISTRY: INDICATION OF SELECTION PREFERENCES AND UNDERDIAGNOSIS
    Papp, Kim
    Gooderham, Melinda
    Beecker, Jennifer
    Lynde, Charles
    Delorme, Isabelle
    Dei-Cas, Ignacio
    Rampakakis, Emmanouil
    Rihakova, Lenka
    Hussein, Shamiza
    Vieira, Antonio
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 48 - 48
12345